

30 September 2026

Tender results – 2025/26 Invitation to Tender

Pharmac has resolved to award or not award tenders for Principal Supply Status for some products included in the 2025/26 Invitation to Tender dated 3 November 2025.

Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceutical under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.


Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12th of October 2026 or the 5th of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12th of the month prior to the date of subsidy change

Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://pharmac.govt.nz/medicine-funding-and-supply/make-an-application/pharmconnect-make-a-medicine-funding-application/process-for-notification-of-product-changes/>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<https://www.pgnz.org.nz/our-trading-arm-psl>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.



2025/26 Invitation to Tender – Principal Supply Status applies until 30 June 2029

Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule


1. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed (no brand change).*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date
Imatinib mesilate	Cap 100 mg; 60 capsule blister pack	\$44.93	\$41.00	Imatinib-Rex (Rex Medical)	1 November 2026	1 April 2027
Imatinib mesilate	Cap 400 mg; 30 capsule blister pack	\$69.76	\$63.00	Imatinib-Rex (Rex Medical)	1 November 2026	1 April 2027
Methotrexate ¹	Inj 100 mg per ml, 50 ml vial; 1 vial pack	\$67.99	\$159.77	Methotrexate Ebewe (Sandoz)	1 November 2026	1 April 2027

¹The subsidy of methotrexate inj 1 mg for ECP (Baxter) will be increased from \$0.06 per 1 mg to \$0.14 per 1 mg from 1 November 2026 in Section B of the Pharmaceutical Schedule.

2. *Tenders awarded to pharmaceuticals where at least one other brand is listed (the funded brand will change).*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date	Brand (Supplier) affected by delisting
Potassium chloride	Inj 75 mg (1 mmol) per ml, 10 ml ampoule; 50 plastic ampoule pack	\$65.00	\$51.30	Potassium Chloride Aborns (Aborns)	1 January 2027	1 June 2027	Juno (Arrotex) Pfizer (Arrotex) LumaCina (Arrotex)




Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

3. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed (no brand change).*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Date of subsidy change	Principal Supply date
Imatinib mesilate	Cap 100 mg; 60 capsule blister pack	\$44.93	\$41.00	Imatinib-Rex (Rex Medical)	5%	1 November 2026	1 April 2027
Imatinib mesilate	Cap 400 mg; 30 capsule blister pack	\$69.76	\$63.00	Imatinib-Rex (Rex Medical)	5%	1 November 2026	1 April 2027
Methotrexate	Inj 100 mg per ml, 50 ml vial; 1 vial pack	\$67.99	\$159.77	Methotrexate Ebewe (Sandoz)	5%	1 November 2026	1 April 2027

4. *Tenders awarded to pharmaceuticals where at least one other brand is listed (the funded brand will change).*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Date of subsidy change	Principal Supply date	Brand (Supplier) affected by delisting
Cefuroxime	Inj 750 mg vial; 10 vial pack	\$8.16	\$7.38	Cefuroxime-AFT (AFT)	5%	1 March 2027	1 August 2027	Cefuroxime Devatis (Devatis)
Cefuroxime	Inj 1.5 g vial; 10 vial pack	\$13.01	\$12.85	Cefuroxime-AFT (AFT)	5%	1 March 2027	1 August 2027	Cefuroxime Devatis (Devatis)




5. *Tenders awarded to currently listed pharmaceuticals where no brand is listed.*

Chemical name	Presentation; Pack size and type	Pack price	Principal Supply brand (Supplier)	DV Limit	Date of listing	Principal Supply date
Potassium chloride	Inj 75 mg per ml, 10 ml ampoule; 50 pack	\$51.30	Potassium Chloride Aborns (Aborns)	5%	1 January 2027	1 June 2027

6. *Tenders awarded to pharmaceuticals not currently listed on the Pharmaceutical Schedule (new investments).*

Chemical name	Presentation; Pack size and type	Pack price	Principal Supply brand (Supplier)	DV Limit	Date of listing	Principal Supply date
Ibuprofen	Tab 200 mg - 20 tablet pack; 20 tablet blister pack	\$0.90	Ibuprofen-AFT (AFT)	5%	1 November 2026	1 June 2027



Tender declines – Products where no tender is to be awarded for Principal Supply Status

Pharmac has resolved not to award tenders for Principal Supply Status for the following product listed in the 2025/26 Invitation to Tender, dated 3 November 2025.

Chemical Name	Line Item
Cefuroxime sodium	Inj 250 mg
Dapsone	Tab 25 mg
Efavirenz with emtricitabine and tenofovir disoproxil (as a fumarate)	Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate)
Efavirenz with emtricitabine and tenofovir disoproxil (as a maleate)	Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate)